Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Inclusion Criteria: * ECOG performance status of 0-1 * Life expectancy of \>3 months according to the investigator's judgment * Solid tumors known for response on Il-2 or Il-10 and/or high expression of EGFR like all Non-small cell Lung, Skin, Head and Neck, Colon, Kidney, Bladder, Pancreatic cancers and all squamous cell carcinoma of other organs can be included with a classical histology report, specific EGFR expression or amplification reports are needed for other solid tumor types like gynecologic, prostate or triple negative breast cancer * Measurable disease, defined as at least one (non-irradiated) lesion measurable on CT/MRI or bone scan as defined by RECIST 1.1. * Progressive disease (PD) at study entry defined as one or more of the following criteria: * Clinical PD with performance decline, clinical symptoms and/or observed tumor growth * PD documented with imaging showing at least 20% growth (largest diameter) and/or new lesions * Adequate cardiovascular, hematological, liver, and renal function. * Subjects have failed one or more lines of systemic therapy and have not been operated on or receiving anti-cancer medication for at least 4 weeks. * Males and females of childbearing potential must agree to use effective contraception starting prior to the first day of treatment and continuing during treatment * Additional criteria may apply Exclusion Criteria: * Subjects with documented diffuse peritoneal disease or persistent abundant ascites * Subjects with known p…